Rifai Muhamad Aly, Moles James K, Short Delmar D
Roanoke-Salem Program, University of Virginia School of Medicine, Roanoke, Virginia, USA.
Psychiatr Serv. 2006 Apr;57(4):570-2. doi: 10.1176/ps.2006.57.4.570.
This study characterized the utilization and outcomes of hepatitis C virus (HCV) treatment among patients with psychiatric illness.
HCV treatment evaluations were tracked among 360 patients with HCV infection and psychiatric illness (substance use disorders, anxiety disorders, affective disorders, or psychotic disorders).
Two-thirds of patients did not receive HCV treatment, 11 percent of patients died during the study period, and 42 percent were excluded from HCV treatment because of nonadherence to the evaluation process or diagnoses of psychiatric and substance use disorders. Interferon-alpha and ribavirin treatment resulted in viral clearance in 10 percent of patients.
A majority of patients with HCV and psychiatric illness did not receive HCV treatment, and HCV infection was associated with significant mortality. Study results highlight the need to develop innovative approaches to engage such patients in HCV treatment and to successfully manage psychiatric illness during HCV treatment.
本研究对患有精神疾病的丙型肝炎病毒(HCV)感染者的治疗利用情况及治疗结果进行了特征分析。
对360例HCV感染且患有精神疾病(物质使用障碍、焦虑症、情感障碍或精神障碍)的患者的HCV治疗评估情况进行了跟踪。
三分之二的患者未接受HCV治疗,11%的患者在研究期间死亡,42%的患者因未坚持评估流程或被诊断患有精神疾病和物质使用障碍而被排除在HCV治疗之外。使用α干扰素和利巴韦林治疗使10%的患者实现了病毒清除。
大多数患有HCV和精神疾病的患者未接受HCV治疗,且HCV感染与显著的死亡率相关。研究结果凸显了开发创新方法以使此类患者参与HCV治疗并在HCV治疗期间成功管理精神疾病的必要性。